Robert Lin

Company: Avista Therapeutics

Job title: Chief Executive Officer

Bio:

Rob Lin, PhD, CFA currently serves as the CEO of Avista Therapeutics and a board member of Avista and BlueSphere Bio.  As a VC with UPMC Enterprises, he led the team’s investments in SparingVision, Code Biotherapeutics, Ring Therapeutics, Avista, BlueSphere, and VegaVect, Inc.

Seminars:

scAAVengr Derived Intravitreal Vectors for Ophthalmic Gene Therapy 12:00 pm

New data on Avista’s lead candidate capsids for intravitreal delivery AI/Machine Learning techniques to identify and optimize capsids Advancement towards clinical indications for Avista’s internal pipelineRead more

day: Conference Day One

De-Risking the Human Translatability Piece of Next-Generation Vectors 8:35 am

Highlighting different approaches to produce robust, translatable data when transitioning through preclinical studies Better understanding disease mechanisms and anticipated clinical responses to guide vector selection and design Exploring more predictive preclinical models (e.g., human cells, organoids, assembloids) for both vector validation and development Outlining the role of vector bioengineering for fit-for-purpose human tissue types Reducing…Read more

day: PRE-CONFERENCE WORKSHOP DAY